Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. daily Stock Chart
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.50 Insider Own11.90% Shs Outstand42.89M Perf Week-1.76%
Market Cap5.04B Forward P/E- EPS next Y-9.03 Insider Trans-10.96% Shs Float36.26M Perf Month9.92%
Income-259.00M PEG- EPS next Q-2.09 Inst Own- Short Float14.16% Perf Quarter40.98%
Sales2.40M P/S2100.35 EPS this Y-78.70% Inst Trans14.60% Short Ratio10.09 Perf Half Y16.75%
Book/sh15.30 P/B7.51 EPS next Y-5.20% ROA-48.90% Target Price118.07 Perf Year8.94%
Cash/sh15.85 P/C7.25 EPS next 5Y- ROE-53.30% 52W Range66.01 - 132.59 Perf YTD-10.81%
Dividend- P/FCF- EPS past 5Y-11.90% ROI- 52W High-13.32% Beta1.82
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low74.11% ATR5.30
Employees111 Current Ratio12.60 Sales Q/Q-75.00% Oper. Margin- RSI (14)53.64 Volatility4.02% 4.94%
OptionableYes Debt/Eq0.00 EPS Q/Q-72.80% Profit Margin- Rel Volume0.81 Prev Close115.82
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume508.76K Price114.93
Recom1.80 SMA201.60% SMA509.86% SMA20021.16% Volume413,710 Change-0.77%
May-01-20Upgrade JP Morgan Neutral → Overweight $116
Apr-16-20Initiated Goldman Buy $151
Mar-12-20Upgrade JP Morgan Underweight → Neutral $88
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Sep-24-19Upgrade Guggenheim Neutral → Buy $116
Sep-09-19Upgrade Jefferies Hold → Buy $89 → $105
Aug-02-19Downgrade JP Morgan Neutral → Underweight $85
Jul-18-19Initiated Deutsche Bank Hold $86
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Jul-06-20 04:52PM  
Jun-17-20 11:00AM  
Jun-16-20 10:09AM  
Jun-12-20 11:54AM  
Jun-06-20 11:31AM  
Jun-05-20 09:00AM  
Jun-03-20 09:45AM  
Jun-02-20 08:59PM  
Jun-01-20 09:07AM  
May-18-20 04:15PM  
May-15-20 08:06PM  
May-07-20 08:00PM  
May-05-20 08:41AM  
May-04-20 01:36PM  
Apr-27-20 12:32PM  
Apr-22-20 02:15PM  
Apr-21-20 04:19PM  
Apr-20-20 07:23AM  
Mar-26-20 01:06PM  
Feb-27-20 10:43AM  
Feb-25-20 08:00AM  
Feb-19-20 10:35AM  
Feb-15-20 11:30AM  
Jan-14-20 04:01PM  
Jan-09-20 10:00PM  
Jan-08-20 04:03PM  
Jan-07-20 07:57AM  
Jan-06-20 04:30PM  
Jan-03-20 01:36PM  
Jan-02-20 04:30PM  
Dec-26-19 11:11AM  
Dec-19-19 10:09AM  
Dec-18-19 08:40AM  
Dec-13-19 07:00AM  
Dec-04-19 08:35PM  
Nov-09-19 06:15PM  
Nov-04-19 06:55PM  
Nov-03-19 07:10AM  
Oct-29-19 07:32AM  
Oct-28-19 04:15PM  
Oct-25-19 11:05AM  
Oct-23-19 04:45PM  
Oct-17-19 09:00AM  
Oct-16-19 04:22PM  
Oct-07-19 06:00AM  
Oct-01-19 09:09AM  
Sep-28-19 08:34AM  
Sep-09-19 10:10AM  
Sep-05-19 09:16PM  
Sep-04-19 09:15AM  
Aug-23-19 10:15PM  
Aug-15-19 04:30PM  
Aug-05-19 04:15PM  
Jul-18-19 07:35AM  
Jul-10-19 05:53PM  
Jul-09-19 04:30PM  
Jul-02-19 07:29AM  
Jul-01-19 04:30PM  
Jun-30-19 08:00AM  
Jun-27-19 04:05PM  
Jun-25-19 08:30AM  
Jun-24-19 04:01PM  
Jun-18-19 07:09AM  
Jun-14-19 08:41AM  
Jun-13-19 11:51AM  
Jun-12-19 10:03AM  
Jun-10-19 10:26AM  
Jun-06-19 03:12PM  
Jun-05-19 07:30AM  
Jun-04-19 03:18PM  
Jun-03-19 02:46PM  
May-31-19 01:04PM  
May-30-19 04:30PM  
May-16-19 04:14PM  
May-14-19 08:42AM  
May-07-19 07:10AM  
Apr-29-19 05:10PM  
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Braslyn Ltd.10% OwnerJun 12Option Exercise0.00600,0066003,135,972Jun 16 05:03 PM
Braslyn Ltd.10% OwnerJun 12Sale69.00600,00041,400,0002,535,966Jun 16 05:03 PM
CARTER BRUCE L ADirectorMay 18Option Exercise6.784,00027,1206,000May 20 05:10 PM
CARTER BRUCE L ADirectorMay 18Sale106.864,000427,4402,000May 20 05:10 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Option Exercise24.9933,334833,01772,735May 13 04:18 PM
CHEN ISANEVP, Chief Medical OfficerMay 11Sale105.0033,3343,500,07039,401May 13 04:18 PM
BAUM CHARLES MPresident & CEOApr 27Option Exercise5.405573,008107,023Apr 28 08:49 PM
Johnson Craig ADirectorApr 20Option Exercise25.8415,000387,60017,000Apr 21 05:26 PM
Johnson Craig ADirectorApr 20Sale93.0015,0001,395,0002,000Apr 21 05:26 PM
BAUM CHARLES MPresident & CEOApr 17Option Exercise8.4940,000339,600146,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOApr 17Sale90.3340,0003,613,109106,466Apr 20 04:59 PM
BAUM CHARLES MPresident & CEOMar 27Option Exercise5.402,29112,371106,466Mar 30 05:52 PM
Christensen JamieEVP, Chief Scientific OfficerMar 26Option Exercise15.518,058124,98332,842Mar 27 05:37 PM
BAUM CHARLES MPresident & CEOFeb 28Option Exercise5.402,29112,371104,175Mar 02 04:28 PM
BAUM CHARLES MPresident & CEOFeb 04Option Exercise15.414,68772,247101,884Feb 06 04:41 PM
CHEN ISANEVP, Chief Medical OfficerJan 29Option Exercise24.993,00275,02039,401Jan 31 08:03 PM
Boxer Capital, LLC10% OwnerJan 10Buy97.5050,0004,875,0001,765,560Jan 14 04:30 PM
BAUM CHARLES MPresident & CEODec 24Option Exercise24.933187,92756,917Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Option Exercise5.446,66636,24613,326Dec 26 06:15 PM
Christensen JamieEVP, Chief Scientific OfficerDec 23Sale125.006,666833,2509,159Dec 26 06:15 PM
CARTER BRUCE L ADirectorNov 20Option Exercise6.783,00020,3403,000Nov 22 04:46 PM
CARTER BRUCE L ADirectorNov 20Sale94.743,000284,2200Nov 22 04:46 PM
GREY MICHAEL GDirectorNov 12Option Exercise16.843,50058,9405,298Nov 14 06:30 PM
GREY MICHAEL GDirectorNov 12Sale102.443,042311,6222,256Nov 14 06:30 PM
BAUM CHARLES MPresident & CEOAug 22Option Exercise8.6752,368454,290117,851Aug 23 06:07 PM
BAUM CHARLES MPresident & CEOAug 22Sale86.2251,8104,467,31266,041Aug 23 06:07 PM
CARTER BRUCE L ADirectorAug 21Option Exercise6.783,00020,3403,000Aug 23 06:01 PM
CARTER BRUCE L ADirectorAug 21Sale89.243,000267,7200Aug 23 06:01 PM
GREY MICHAEL GDirectorAug 12Option Exercise16.843,50058,9404,840Aug 14 07:30 PM
GREY MICHAEL GDirectorAug 12Sale92.273,042280,6971,798Aug 14 07:30 PM
Avoro Capital Advisors LLC10% OwnerJul 23Sale101.8862,5006,367,5003,800,000Jul 25 04:33 PM
Boxer Capital, LLC10% OwnerJul 17Sale98.30725,00871,268,328990,560Jul 19 09:39 PM